Drug development in pemphigoid diseases

Katja Bieber; Ralf J. Ludwig

doi:10.2340/00015555-3400

Drug development in pemphigoid diseases

Katja Bieber, Ralf J. Ludwig^*

^*Corresponding author for this work

Institute of Experimental Dermatology

11 Citations (Scopus)

Abstract

Pemphigoid diseases are organ-specific autoimmune diseases of the skin and/or mucous membranes. They are caused by autoantibodies targeting adhesion molecules located at the dermal–epidermal junction. While the diagnostics of pemphigoid diseases and insights into their pathogenesis have improved significantly, the development of novel treatments that are effective and safe remains an unmet medical need. However, numerous pre-clinical studies and early clinical trials have recently been launched. This review summarizes some pathways leading to drug development in pemphigoid diseases, namely: (i) hypothesis-driven drug development; (ii) omics-based drug development; (iii) drug repurposing; (iv) screening-based drug development; and (v) drug development based on careful clinical observations. Ultimately, it is hoped that this will lead to personalized and curative treatments.

Original language	English
Article number	adv00055
Journal	Acta Dermato-Venereologica
Volume	100
Issue number	5
Pages (from-to)	108-114
Number of pages	7
ISSN	0001-5555
DOIs	https://doi.org/10.2340/00015555-3400
Publication status	Published - 12.02.2020

Funding

This work has been financially supported by the Research Training Group “Modulation of Autoimmunity” (GRK 1727) and the Excellence Clusters “Inflammation at Interfaces” (EXC 306), and “Precision Medicine in Chronic Inflammation” (EXC 2167), all from the Deutsche Forschungsgemeinschaft. RJL has received research funding from Miltenyi Biotec, Biogen, Biotest, Almirall, True North Therapeutics, UCB Pharma, ArgenX, TxCell, Topadur, Incyte and Admirx and fees for consulting or speaking from ArgenX, Immunogenetics, Novartis and Lilly. KB consults for ArgenX.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Access to Document

10.2340/00015555-3400

Cite this

@article{da3cc3f34a6d48cfad8220827fa1b6c2,

title = "Drug development in pemphigoid diseases",

abstract = "Pemphigoid diseases are organ-specific autoimmune diseases of the skin and/or mucous membranes. They are caused by autoantibodies targeting adhesion molecules located at the dermal–epidermal junction. While the diagnostics of pemphigoid diseases and insights into their pathogenesis have improved significantly, the development of novel treatments that are effective and safe remains an unmet medical need. However, numerous pre-clinical studies and early clinical trials have recently been launched. This review summarizes some pathways leading to drug development in pemphigoid diseases, namely: (i) hypothesis-driven drug development; (ii) omics-based drug development; (iii) drug repurposing; (iv) screening-based drug development; and (v) drug development based on careful clinical observations. Ultimately, it is hoped that this will lead to personalized and curative treatments.",

author = "Katja Bieber and Ludwig, \{Ralf J.\}",

year = "2020",

month = feb,

day = "12",

doi = "10.2340/00015555-3400",

language = "English",

volume = "100",

pages = "108--114",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Medical Journals Sweden AB",

number = "5",

}

TY - JOUR

T1 - Drug development in pemphigoid diseases

AU - Bieber, Katja

AU - Ludwig, Ralf J.

PY - 2020/2/12

Y1 - 2020/2/12

N2 - Pemphigoid diseases are organ-specific autoimmune diseases of the skin and/or mucous membranes. They are caused by autoantibodies targeting adhesion molecules located at the dermal–epidermal junction. While the diagnostics of pemphigoid diseases and insights into their pathogenesis have improved significantly, the development of novel treatments that are effective and safe remains an unmet medical need. However, numerous pre-clinical studies and early clinical trials have recently been launched. This review summarizes some pathways leading to drug development in pemphigoid diseases, namely: (i) hypothesis-driven drug development; (ii) omics-based drug development; (iii) drug repurposing; (iv) screening-based drug development; and (v) drug development based on careful clinical observations. Ultimately, it is hoped that this will lead to personalized and curative treatments.

AB - Pemphigoid diseases are organ-specific autoimmune diseases of the skin and/or mucous membranes. They are caused by autoantibodies targeting adhesion molecules located at the dermal–epidermal junction. While the diagnostics of pemphigoid diseases and insights into their pathogenesis have improved significantly, the development of novel treatments that are effective and safe remains an unmet medical need. However, numerous pre-clinical studies and early clinical trials have recently been launched. This review summarizes some pathways leading to drug development in pemphigoid diseases, namely: (i) hypothesis-driven drug development; (ii) omics-based drug development; (iii) drug repurposing; (iv) screening-based drug development; and (v) drug development based on careful clinical observations. Ultimately, it is hoped that this will lead to personalized and curative treatments.

UR - https://www.scopus.com/pages/publications/85080851062

U2 - 10.2340/00015555-3400

DO - 10.2340/00015555-3400

M3 - Journal articles

C2 - 32039458

AN - SCOPUS:85080851062

SN - 0001-5555

VL - 100

SP - 108

EP - 114

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 5

M1 - adv00055

ER -

Drug development in pemphigoid diseases

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this